Podcast: Beyond CRISPR and gene therapy—How ‘gene writing’ is poised to transform the treatment of even the rarest diseases

screenshot gene writing
Credit: Tessera Therapeutics
In just a few short years, gene editing has launched a biomedical revolution, yielding previously unimaginable treatments for conditions ranging from sickle cell disease to blindness. But for all its capabilities, the technology is limited by an important drawback: it typically can only disrupt a deleterious gene underlying a specific trait. So what do scientists do when editing a patient’s existing DNA won’t solve the problem? Write new genes.

Related article:  Why marijuana might not be such a great weapon to fight opioid addiction

The next step in the evolution of genetic medicine, gene writing exploits a natural process in cells that allows researchers to install genes of interest, replacing damaged DNA sequences that cause debilitating diseases and may not be treatable with other genetic engineering tools. According to Tessera Theraputics, a biotech startup working to harness the new technology’s potential:

RNA gene writers can change base pairs, make small insertions or deletions, and integrate entire genes into the genome …. This flexibility means that in the future, we could cure rare genetic disorders with treatments that are easily distributed, manufactured at scale, and re-dosed if necessary.

Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.

On this episode of Talking Biotech, Dr. Geoff von Maltzhan of Tessera joins host Kevin Folta to explain how gene writing works and highlight its most promising medical applications.

 

Dr. Geoffrey von Maltzahn is co-founder, Chief Executive Officer, and Director of Tessera Therapeutics, as well as a General Partner at Flagship Pioneering, where he focuses on inventing technologies and starting companies to address global challenges in medicine and environmental sustainability. Find Geoffrey on Twitter @GVMaltzahn

Kevin M. Folta is a professor in the Horticultural Sciences Department at the University of Florida. Follow Professor Folta on Twitter @kevinfolta

The Talking Biotech podcast, produced by Kevin Folta, is available for listening or subscription:

Apple Podcasts | Android | Email | Google Podcasts | Stitcher | RSS | Player FM | Pod Directory | TuneIn

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: What are mRNA COVID-19 vaccines and how do they work?

Infographic: What are mRNA COVID-19 vaccines and how do they work?

As of 1 December 2020, thirteen vaccines have reached the final stage of testing: where they are being given to ...
favicon

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend